Brief: NanoCarrier affirms safety profile and efficacy of NC-6004 in Phase Ib clinical study in US

Nano Holdings

11/10/2016 06:42

Oct 11 (Reuters) - NanoCarrier Co Ltd   4571.T :  
     
     
    * Says it confirmed safety profile and efficacy of NC-6004 
in the Phase Ib clinical study conducted in the U.S. 
     
     
    Source text in Japanese:https://goo.gl/XsXi3w 
    Further company coverage: 4571.T  
 
 (Beijing Headline News) 
 ((Beijing.HeadlineNews@thomsonreuters.com; +86 10 62674724; 
Reuters Messaging: jun.cao.reuters.com@reuters.net))